KPTI News and Press, Karyopharm Therapeutics Inc. From 04/30/20

Karyopharm Therapeutics ( KPTI -5.3% ) is collaborating with contract research organization (CRO) PROMETRIKA on an international, randomized, 230-subject study evaluating low-dose Xpovio (selinexor) in severely ill hospitalized COVID-19 patients. More news on: Karyopharm Therapeutics I...

Cambridge, MA-based clinical research organization to be responsible for Clinical Trial Site Management and On-Site Monitoring in the United States PROMETRIKA ( www.prometrika.com ), a leading clinical research organization, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ...

- A Total of Five Abstracts Selected for Presentation, Including Two Highlighting Data from the Darzalex® and Kyprolis® Arms of the Phase 1b/2 STOMP Study - NEWTON, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven&#x...

SYDNEY, Apr 29, 2020 - (ACN Newswire) - The Asia-Pacific's largest specialist biotech CRO Novotech has been engaged for a Phase 2 COVID-19 study by biotech sponsor Karyopharm Therapeutics Inc. The Phase 2 randomized, open-label, multicenter study will evaluate the activity and safety of two r...

-- Conference Call Scheduled for Tuesday, May 5, 2020, at 8:30 a.m. ET -- NEWTON, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that it will report first quarter 2020 financial results on Tuesday, May 5, 2020. Karyopharm'...

Stocks in the biotech sector have generally held up well during the market sell-off caused by the COVID-19 pandemic. Two of the leading biotechnology exchange-traded funds (ETFs), the  iShares Nasdaq Biotechnology ETF and the  SPDR S&P Biotech ETF , have quickly rebounded from the...

-- First Study of an XPO1 Inhibitor to Treat Patients with Severe Viral Infections   -- Precision for Medicine Responsible for Clinical Trial Management in Europe BUDAPEST, Hungary , April 22, 2020 /PRNewswire/ -- Precision for Medicine, a pioneer in the design, develop...

The first subject has been dosed in a Phase 2 study assessing Karyopharm Therapeutics' (NASDAQ: KPTI ) selinexor in severely ill COVID-19 patients. Total enrollment should be ~230. More news on: Karyopharm Therapeutics Inc., Healthcare stocks news, Read more ...

NEWTON, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced dosing of the first patient in a randomized Phase 2 clinical study evaluating low dose oral selinexor in hospitalized patients with severe COVID-19. This global study is expected to ...

Deals and Financings Leo Pharma, a Denmark dermatology company, acquired global rights to a novel treatment for atopic dermatitis ((AD)) and allergic asthma in an agreement worth up to $570 million. FB825 is a first-in-class candidate that targets the CεmX domain of membrane-bound IgE...